Dawson, Amy
Zarou, Martha M. https://orcid.org/0000-0003-0152-1599
Prasad, Bodhayan https://orcid.org/0000-0002-7383-2460
Bittencourt-Silvestre, Joana
Zerbst, Désirée
Himonas, Ekaterini https://orcid.org/0000-0002-5188-8930
Hsieh, Ya-Ching
van Loon, Isabel
Blanco, Giovanny Rodriguez
Ianniciello, Angela
Kerekes, Zsombor
Krishnan, Vaidehi https://orcid.org/0000-0002-5028-6567
Agarwal, Puneet https://orcid.org/0000-0003-1688-3840
Almasoudi, Hassan
McCluskey, Laura
Hopcroft, Lisa E. M. https://orcid.org/0000-0002-7022-1322
Scott, Mary T. https://orcid.org/0000-0002-7177-6960
Baquero, Pablo
Dunn, Karen https://orcid.org/0000-0002-6532-970X
Vetrie, David https://orcid.org/0000-0003-2075-4662
Copland, Mhairi https://orcid.org/0000-0002-7655-016X
Bhatia, Ravi https://orcid.org/0000-0001-5740-2316
Coffelt, Seth B. https://orcid.org/0000-0003-2257-2862
Tiong, Ong Sin https://orcid.org/0000-0001-9460-3483
Wheadon, Helen https://orcid.org/0000-0001-9902-3170
Zanivan, Sara
Kirschner, Kristina https://orcid.org/0000-0001-7607-8670
Helgason, G. Vignir https://orcid.org/0000-0003-1616-132X
Funding for this research was provided by:
Kay Kendall Leukaemia Fund (KKL698)
Cancer Research UK (A29754, A29800)
Article History
Received: 29 April 2022
Accepted: 25 January 2024
First Online: 5 February 2024
Competing interests
: M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals. All other authors declare no competing interests.